ZOLL® Medical Corporation, an Asahi Kasei Group Company that
manufactures medical devices and related software solutions, today
announced it has acquired TherOx, Inc., of Irvine, Calif., a privately
held company. TherOx is focused on improving treatment of acute
myocardial infarction (AMI) and markets systems to deliver
SuperSaturated Oxygen (SSO2) Therapy.
This press release features multimedia. View the full release here:
SuperSaturated Oxygen (SSO2) Therapy (Photo: Business Wire)
SSO2 Therapy, which was recently approved by the Federal Drug
Administration (FDA), has been demonstrated to reduce infarct size after
primary coronary intervention (PCI) with stenting in patients with left
anterior descending ST-elevation myocardial infarction.1 When
a large ischemic area of muscle damage remains following AMI, the
patient condition often deteriorates into debilitating heart failure.
"ZOLL and TherOx are both focused on emergency cardiac care," said Neil
Johnston, President of ZOLL Circulation. "This acquisition expands the
ZOLL product portfolio in support of excellence for patients and
"SSO2 Therapy can help reduce infarct size among
patients who suffer from large anterior AMIs,1 which are the
most serious heart attacks,” said Kevin T. Larkin, President and Chief
Executive Officer of TherOx. “Adjunctive to PCI, SSO2 Therapy
is intended to salvage heart muscle and reduce infarct size.”
“We are looking forward to becoming part of ZOLL so that together we can
bring this breakthrough treatment option to more patients sooner,”
“No delay in door-to-balloon times and improved clinical outcomes is a
combination we think physicians will find appealing,” Johnston added.
“Because SSO2 Therapy is delivered following PCI and
stenting, there is no disruption of today’s workflow in the cath lab.”
About SSO2 Therapy
A heart attack is typically caused when oxygenated blood flow to the
heart is blocked or reduced. Most often, the heart’s tiny capillaries
then swell, further restricting blood flow. If not quickly restored,
irreversible damage to the heart muscle, or infarction, will occur.
Immediately after the coronary artery has been opened by PCI, SSO2
Therapy delivers a one-time, 60-minute infusion of the patient’s super
oxygenated blood to the targeted ischemic area of the heart through a
small catheter. SSO2 Therapy infuses super oxygenated blood
to improve microvascular flow, then restores heart tissue to normal
oxygen level.2,3. SSO2 Therapy is aligned with
current guidelines for interventional cardiology procedures.
About TherOx, Inc.
TherOx is focused on commercializing SSO2 Therapy for the
sizeable AMI patient population to save hearts, improving and ultimately
saving lives. This first-of-its-kind device treats the most serious
heart attack patients who suffer from acute myocardial infarction
without interrupting door-to-balloon time. TherOx technology provides
highly oxygenated fluids directly to the damaged area of the heart using
a catheter placed after PCI and stenting. Clinical trials show
consistent benefit to the patient, as relevant to the standard of care,
and a reduction in infarct size of 26%.1 For more information
about TherOx, visit www.therox.com.
About ZOLL Medical Corporation
ZOLL Medical Corporation, an Asahi Kasei Group company, develops and
markets medical devices and software solutions that help advance
emergency care and save lives, while increasing clinical and operational
efficiencies. With products for defibrillation and monitoring,
circulation and CPR feedback, data management, fluid resuscitation,
therapeutic temperature management, and ventilation, ZOLL provides a
comprehensive set of technologies that help clinicians, EMS and fire
professionals, and lay rescuers treat victims needing resuscitation and
acute critical care. For more information, visit www.zoll.com.
About Asahi Kasei
The Asahi Kasei Group is a diversified group of companies led by holding
company Asahi Kasei Corp., with operations in the material, homes, and
health care business sectors. Its health care operations include devices
and systems for acute critical care, dialysis, therapeutic apheresis,
transfusion, and manufacture of biotherapeutics, as well as
pharmaceuticals and diagnostic reagents. With more than 30,000 employees
around the world, the Asahi Kasei Group serves customers in more than
100 countries. For more information, visit www.asahi-kasei.co.jp/asahi/en/.
1 Stone GW, et al. Circ Cardiovasc Interv; 2; 366-375.
2 Spears JR, et al. ASAIO Jour. 2003
3 Bartorelli A, et al. Am Jour
of Cardio Drugs. 2003. 3(4); 253-263.
Copyright © 2019 ZOLL Medical Corporation. All rights reserved. TherOx
and ZOLL are trademarks or registered trademarks of ZOLL Medical
Corporation in the United States and/or other countries. Asahi Kasei is
a registered trademark of Asahi Kasei Corporation. All other trademarks
are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190618005133/en/